UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 49

Sortiert nach

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

The New England journal of medicine, 2011-10, Vol.365 (14), p.1293-1303

2011

Volltextzugriff (PDF)

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet neurology, 2014-03, Vol.13 (3), p.247-256

2014

Volltextzugriff (PDF)

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet neurology, 2014-10, Vol.13 (10), p.977-986

2014

Volltextzugriff (PDF)

Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience

Multiple sclerosis, 2020-06, Vol.26 (7), p.829-836

2020

Volltextzugriff (PDF)

Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials

Multiple sclerosis, 2020-08, Vol.26 (9), p.1083-1092

2020

Volltextzugriff (PDF)

Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial

Multiple sclerosis, 2023-03, Vol.29 (3), p.385-394

2023

Volltextzugriff (PDF)

Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS

Multiple sclerosis, 2024-06, Vol.30 (7), p.833-842

2024

Volltextzugriff (PDF)

Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide

Frontiers in neurology, 2022-02, Vol.13, p.828616-828616

2022

Volltextzugriff (PDF)

The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies

Multiple sclerosis, 2018-04, Vol.24 (4), p.535-539

2018

Volltextzugriff (PDF)

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

Multiple sclerosis, 2014-05, Vol.20 (6), p.705-716

2014

Volltextzugriff (PDF)

Inhibition of CD40L with Frexalimab in Multiple Sclerosis

The New England journal of medicine, 2024-02, Vol.390 (7), p.589-600

2024

Volltextzugriff (PDF)

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis

Neurology, 2013-08, Vol.81 (6), p.552

2013

Volltextzugriff (PDF)

Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide

Reproductive toxicology (Elmsford, N.Y.), 2020-08, Vol.95, p.45-50

2020

Volltextzugriff (PDF)

Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial

Lancet neurology, 2021-12, Vol.20 (12), p.1001-1011

2021

Volltextzugriff (PDF)

Taux plasmatique des neurofilaments à chaîne légère chez les enfants atteints de sclérose en plaques récurrente-rémittente traités par tériflunomide ou placebo : une analyse post hoc de l’essai randomisé TERIKIDS

Revue neurologique, 2022-04, Vol.178, p.S117-S117

2022

Volltextzugriff (PDF)

ANALYSIS OF THE TOPIC STUDY USING 2010 MCDONALD CRITERIA

Journal of neurology, neurosurgery and psychiatry, 2015-11, Vol.86 (11), p.e4-e4

2015

Volltextzugriff (PDF)

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide

Multiple sclerosis, 2013-09, Vol.19 (10), p.1310-1319

2013

Volltextzugriff (PDF)

Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study

Neurology, 2016-03, Vol.86 (10), p.920

2016

Volltextzugriff (PDF)

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

Multiple sclerosis, 2012-09, Vol.18 (9), p.1278-1289

2012

Volltextzugriff (PDF)

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis

Multiple sclerosis, 2012-11, Vol.18 (11), p.1625-1632

2012

Volltextzugriff (PDF)

TERIFLUNOMIDE IN EARLY STAGE MS: RESULTS FROM TOPIC

Journal of neurology, neurosurgery and psychiatry, 2014-10, Vol.85 (10), p.e4-e4

2014

Volltextzugriff (PDF)

Données des grossesses chez les patientes atteintes de SEP traitées par tériflunomide : études cliniques et données post-commercialisation

Revue neurologique, 2019-04, Vol.175, p.S93-S93

2019

Volltextzugriff (PDF)

Impact limité à long terme du teriflunomide sur les numérations lymphocytaires et les infections dans les essais poolées TEMSO et TOWER princeps et d’extension

Revue neurologique, 2019-04, Vol.175, p.S100-S100

2019

Volltextzugriff (PDF)

Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens

Neurology : neuroimmunology & neuroinflammation, 2015-04, Vol.2 (2), p.e70

2015

Volltextzugriff (PDF)

Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions

Multiple sclerosis and related disorders, 2016-01, Vol.5, p.97-104

2016

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(49)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(30)
Life Sciences & Biomedicine
(29)
Humans
(22)
Clinical Neurology
(21)
Neurosciences & Neurology
(21)
Adult
(19)
Multiple Sclerosis
(19)
Female
(17)
Male
(17)
Teriflunomide
(17)
Neurology
(14)
Neurosciences
(13)
Multiple Sclerosis, Relapsing-Remitting - Drug Therapy
(12)
Medicin Och Hälsovetenskap
(11)
Double-Blind Method
(10)
Middle Aged
(10)
Treatment Outcome
(10)
Magnetic Resonance Imaging
(9)
Toluidines - Administration & Dosage
(9)
Biological And Medical Sciences
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience

Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials

Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial

Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS

Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide

The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

Inhibition of CD40L with Frexalimab in Multiple Sclerosis

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis

Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide

Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial

Taux plasmatique des neurofilaments à chaîne légère chez les enfants atteints de sclérose en plaques récurrente-rémittente traités par tériflunomide ou placebo : une analyse post hoc de l’essai randomisé TERIKIDS

ANALYSIS OF THE TOPIC STUDY USING 2010 MCDONALD CRITERIA

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide

Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis

TERIFLUNOMIDE IN EARLY STAGE MS: RESULTS FROM TOPIC

Données des grossesses chez les patientes atteintes de SEP traitées par tériflunomide : études cliniques et données post-commercialisation

Impact limité à long terme du teriflunomide sur les numérations lymphocytaires et les infections dans les essais poolées TEMSO et TOWER princeps et d’extension

Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens

Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions

Suchergebnisse filtern